Oncotarget published "A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer" which reported that a recent study revealed that a high De Ritis ratio was a risk factor in some solid malignancies.
This Oncotarget study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC.
This Oncotarget study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC
Among these patients, 32 patients developed recurrent disease and 15 patients showed progression.
A multivariate analysis revealed that non-BCG treatment was an independent risk factor for recurrence, and a higher De Ritis ratio was an independent risk factor for cancer progression.
The De Ritis ratio might be a risk factor for progression in high-risk NMIBC.
The De Ritis ratio might be a risk factor for progression in high-risk NMIBC
Dr. Takashi Kawahara from The Yokohama City University Medical Center said, "Bladder cancer is the eleventh most common malignant disease in the world, and non-muscle invasive bladder cancer (NMIBC) accounts for 75% of all bladder cancer cases."
The serum aspartate aminotransaminase /alanine aminotransaminase ratio was first reported by De Ritis in 1957, since then this ratio has been called the De Ritis ratio.
A high De Ritis ratio was reported to be a poor prognostic marker in some solid malignancies.
In genitourinary cancer, a high De Ritis ratio was reported to be a poor prognostic marker in prostate, renal, and urothelial carcinoma.
In other solid malignancies including breast and lung cancer, a high De Ritis ratio was also reported to be a poor prognostic marker.
Figure 3: The Kaplan Meier curve for progression.
This study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC.
The Kawahara Research Team concluded in their Oncotarget Research Output that first, the study was retrospective in nature.
To reveal the usefulness of the De Ritis ratio as a biomarker, a longer-term study of a larger population with a prospective design should be performed.
Third, this study showed higher age in the higher De Ritis group.
No previous study showed the correlation between AST/ALT value and age.
Thus, further study is needed.
DOI - https://doi.org/10.18632/oncotarget.27944
Full text - https://www.oncotarget.com/article/27944/text/
Correspondence to - Takashi Kawahara - [email protected]
Keywords - AST, ALT, De Ritis, high risk NMIBC
About Oncotarget
Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.
To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:
SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls
Media Contact
[email protected]
18009220957x105
